Bone Therapeutics will host the Annual General Meeting and Extraordinary General Meeting on June 8, 2022

REGULATED INFORMATION

The preliminary documents for the Annual and Extraordinary General Meeting have been made available on the company’s website

Mont-Saint-Guibert, Belgium, 9 May 2022, 7am THISST- BONE THERAPEUTIC (Euronext Brussels and Paris: BOTHE), a cell therapy company responding to unmet medical needs in orthopaedics, invites its shareholders and holders of registered subscription rights and registered convertible bonds of the Company to the General Meeting to be held this Wednesday June 8, 2022 from 4:00 p.m. CESTat Rue Granbonpré 11, Building H1435 Mont-Saint-Guibert, Belgium.

Bone therapy also invites its shareholders and holders of registered subscription rights and registered convertible bonds of the Company to the extraordinary general meeting to be held the same day from 6:00 p.m. CEST, at Rue du Fort 24, 6000 Charleroi, Belgium. If the quorum is not reached at this extraordinary general meeting, a second extraordinary general meeting will be convened and held on June 27, 2022 from 11:00at Rue du Fort 24, 6000 Charleroi, Belgium.

Notices of meetings, including the agenda and voting proposals, are published today in the Belgian instructor and La Libre Belgique.

The preliminary documents and information relating to these meetings have been made available and can be consulted on the Bone Therapeutics website, Investors / General Meeting section, in accordance with the applicable legal and regulatory provisions.

It is also possible to receive the documents free of charge upon request by email to [email protected] or by telephone on +32 (0)493 09 73 66. The documents are also available at the Company’s registered office, Rue Granbonpré 11, Building H1435 Mont-St-Guibert, Belgium.

On Bone therapy

Bone therapy is a leading biotechnology company focused on developing innovative products to address high unmet needs in orthopedics and other diseases. Currently Bone therapy is concentrateing specifically on the development of its most advanced clinical asset, the allogeneic cell therapy platform, ALLOB.

Bone Therapeutics’ core technology is based on its state-of-the-art allogeneic cell and gene therapy platform with differentiated mesenchymal stromal cells (MSCs) from bone marrow that can be stored at the point of use in the hospital. His The lead investigational drug, ALLOB, represents a proprietary and unique approach to bone regeneration that transforms undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced through Bone Therapeutics’ scalable manufacturing process. Following the approval of the CTA by the regulatory authorities in Europe, the Company has initiated the recruitment of patients for the Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, thanks to its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by an extensive IP (Intellectual Property) portfolio spanning ten patent families as well as know-how. The Company is based in the Louvain-la-New science park in Mont Saint Guibert, Belgium. Further information is available at www.bonetherapeutics.com.

For more information, please contact:

Bone Therapeutics SAMiguel ForteMD, PhD, Chief Executive Officer
Tel: +32 (0)493 09 73 66
[email protected]

For Belgian media and investor enquiries:
Bepublic
Bert Bouserie
Tel: +32 (0)488 40 44 77
[email protected]

International Media Requests:
Image box communicationNeil Hunter / michelle boxallTel: +44 (0)20 8943 4685
[email protected] / [email protected]

For French media and investor enquiries:
NewCap Investor Relations & Financial communication
Peter Lawrence, Louis Victor Delouvrier and Arthur Rusty
Tel: +33 (0)1 44 71 94 94
[email protected]

Certain statements, beliefs and opinions contained in this press release are forward-looking and reflect the current expectations and projections of the Company or, if applicable, the directors of the Company regarding future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors, including but not limited to changes in demand, competition and technology, may cause actual events, performance or results to differ materially from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Accordingly, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to the forward-looking statements contained in this press release. as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which such forward-looking statements are based. Neither the Company, nor its advisers or representatives, nor any of its subsidiaries or the officers or employees of such persons warrant that the assumptions underlying these forward-looking statements are free from error and accept no responsibility for the future accuracy of forward-looking statements. statements contained in this press release or the actual occurrence of anticipated developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

©OMX, source GlobeNewswire – EU Press Releases

Comments are closed.